I ntravascular or implantable access devices (IVADs) are essential in the appropriate treatment of patients with a wide range of disease processes. Central venous catheters (CVCs) can provide durable shortterm or long-term solutions, thus obviating the need for repeated peripheral sticks. CVC access is established in patients who are unable to maintain sustainable peripheral intravenous access, for the administration of drugs toxic to the peripheral veins, for patients who require frequent blood draws, and for apheresis or dialysis. If shortterm therapy is warranted, then a non-tunneled CVC may be placed. Alternatively, if longer term therapy is desired, then a tunneled CVC (TCVC) or subcutaneous, implanted port (port-CVC) may be placed. Typically, these procedures are performed by Vascular and Interventional Radiologists.
Performing an interventional procedure entails a commitment from Interventional Radiology physicians to perform a patient assessment, determine the most appropriate catheter that will ensure excellent treatment, and provide long-term care after catheter placement. CVCs are not always a perfect solution, because they are prone to infection and dysfunction. 1 The objective of this article is to discuss indications for CVC placement, implantation techniques, potential complications, and management of catheter-dysfunction through the lens of an Interventional Radiologist.
INDICATIONS AND OPTIONS

Non-tunneled CVCs
The indications for CVC are noted above. Non-tunneled CVCs should be considered for short-term therapeutic apheresis, approximating less than 2 weeks given the high risk of infection. 2 Non-tunneled, double-lumen hemodialysis catheters (10-13.5 French) provide adequate flow for centrifuge-based and filter-based apheresis systems. 3 Soft silastic catheters are not suitable for high-flow therapies, because the lumens tend to collapse with negative pressures. 4 Non-tunneled catheters are designed to be temporary in nature and thus can be placed even in the setting of systemic infections. Current standards of practice for the management of coagulation status and hemostasis risks in any percutaneous image-guided interventions are based on consensus statements from the Society of Interventional Radiology. According to those guidelines, the general recommendation for non-tunneled catheter placement is an international normalized ratio (INR) of less than 2.0 and platelet count of 50,000 K/cumm. 5 However, it is important to note that there are no concise data to provide a specific minimum threshold platelet count for the procedure; therefore, in a setting of severe thrombocytopenia, the decision for platelet transfusion is often left to the discretion of the operator. In general, for nontunneled catheter placements in patients with thrombocytopenic, a platelet count of at least 20,000 K/cumm is recommended. 6, 7 In urgent settings, uncorrected coagulopathy does not preclude catheter placement in unstable patients. If longer term access is needed, then a tunneled catheter should be considered.
Tunneled CVCs
Tunneled-cuffed venous catheters (TCVCs) are indicated for access required for greater than 3 weeks' in duration. 8 Infection rates are significantly lower for tunneled versus non-tunneled catheters. 9 TCVCs are best suited for patients with hematologic malignancies who require stem cell transplantation or long-term therapeutic apheresis. TCVCs also are used in patients with end-stage renal disease (ESRD) who require long-term hemodialysis. Most TCVCs are double-lumen catheters derived from polyurethane or silicone. These materials have high elasticity. In particular, polyurethane catheters have sufficient rigidity to withstand the high flow rates (30-400 mL/minute) necessary for treatment.
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In addition, the polyester (Dacron) cuff of the catheter allows for incorporation of the catheter into the subcutaneous tissue, serving to secure the catheter in position and providing a mechanical barrier against bacterial colonization. 10 According to the Society of Interventional Radiology consensus statement, an INR less than 1.5 and platelet count greater than 50,000 K/cumm are recommended for placement. 5 Again, it is important to point out that these are general guidelines. It has been reported that the placement of TCVCs in coagulopathic patients with INRs between 1.5 and 2.0 and platelet counts of 25,000 K/cumm to 50,000 K/cumm can be safe even without coagulation product transfusions. 11 Currently, there is no strong evidence recommending prophylactic plasma infusion before catheter placement in patients with abnormal coagulopathy; therefore, this is left to the discretion of the referring clinician and the operating physician. 12 Because the TCVC is an implanted device, TCVCs should not be placed in patients who have systemic infections or are acutely sick (e.g.. patients in the Intensive Care Unit).
Subcutaneous ports
The typical indication for port placement (port-CVC) is for patients with an underlying malignancy in need of long courses of chemotherapy infusion. Additional indications include the need for frequent blood transfusions, red blood cell exchange, therapeutic apheresis, and intermittent long-term access. Single-lumen and double-lumen ports are available for placement. High-flow ports have been used for apheresis in adults and children. 13 New designs of subcutaneous implanted ports can tolerate the high flows required for therapeutic apheresis. Advantages over external lines include infection rates and improved quality of life. Disadvantages include painful, large-bore needle puncture of the reservoir for each treatment. 4, 13 Ports are constructed as either single or double lumen using titanium, plastic, silicone, or a combination of these materials. In one study, the infection rate for TCVC was ten-fold that of a subcutaneous port.
14 There are powerinjectable and non-power-injectable ports. The powerinjectable port allows for high injection rates for contrastenhanced computer tomographic examinations. Finally, there are newer, commercially available "low-profile" ports. These smaller ports are suitable for very thin patients, in whom making a sufficient subcutaneous pocket can be challenging at times. Like with TCVCs, an INR less than 1.5 and a platelet count greater than 50,000 K/cumm are recommended for subcutaneous port placement. 5 Absolute contraindications for placement are patients with active systemic infection or uncorrectable coagulopathy. 1 
INSERTION TECHNIQUE
Before catheter placement, a site of venous access is determined. The right internal jugular vein is the most frequently used for central venous access, because of safety and ease of visualization using ultrasound guidance. It also provides the most direct path to the right atrium, minimizing the risk of catheter kinking or pinch-off. Subclavian vein access can be obtained under sonographic or fluoroscopic guidance using landmarks.
However, subclavian access is more technically challenging and has fallen out of favor due to potential complications. 15 It is important to note that subclavian access also is not optimal for patients who have chronic kidney failure or ESRD, because maintaining patency of the vein is essential for longevity of arteriovenous fistula or grafts that may subsequently be created for hemodialysis. 16 Femoral venous access is most often obtained in more emergent or intensive care settings. Catheter care should be more vigilant because of the greater risk of infection pertaining to the location of the catheter. 17 
Non-tunneled central venous access
Almost all non-tunneled CVC placements can be done with local anesthesia. However, for combative or extremely anxious patients, short-acting anxiolytics (e.g., midazolam) can be administered to facilitate catheter placement in a safe manner.
Under direct ultrasound guidance, access into the vein is obtained using a 21-gauge micropuncture needle. Using the Seldinger technique, the micropuncture needle is then exchanged for a 4-French micropuncture sheath over a 0.018-inch microwire. Under fluoroscopy, the tip of the microwire is placed at the cavoatrial junction, and the intravascular length from the tip of the wire to the access site is measured. This estimate allows for selection of the appropriate length catheter. For most CVCs, the recommended position is at the cavoatrial junction, which is usually about two vertebral bodies below the carina on fluoroscopy examination. Next, a 0.035-inch guidewire is passed through the micropuncture sheath into the inferior vena cava under fluoroscopic guidance. Working with the guidewire above the inferior cavoatrial junction is not optimal, because the guidewire can trigger cardiac arrhythmias. For large-bore catheters, such as temporary hemodialysis or apheresis catheters, the venotomy is serially dilated to the appropriate size for the catheter (usually to 14-French). Then, the catheter is advanced over the guidewire to the level of the cavoatrial junction. A final fluoroscopic image is obtained to document appropriate positioning of the newly placed catheter.
Tunneled CVCs
Most TCVCs can be placed under moderate sedation with nurse monitoring, using intravenous midazolam and fentanyl. The right internal jugular vein remains the preferred site of access. Central venous access can be very challenging in patients with ESRD, because some have exhausted the usual sites for venous access. Thus, pre-procedure ultrasound is important for identifying the optimal access site.
The access technique into the vein with TCVCs is the same as that used non-tunneled catheters. Some duallumen tunneled catheters have split end tips, which are placed into the right atrium to allow for better flow rates.
The subcutaneous tissue tract is planned and anesthetized. Ideally, the catheter exit site is two finger breaths from the glenohumeral joint and two finger breaths below the clavicle. Some tunneled catheters come in predetermined lengths. In addition to the total length of the catheter, a tip-to-cuff length is provided, which needs to account for both the intravascular length required and the length of the subcutaneous tunnel (length from the catheter exit site to the neck dermatotomy site). Using blunt dissection, the catheter is tunneled in a retrograde fashion subcutaneously to the neck incision and pulled through the incision. The venotomy is serially dilated, and the catheter is inserted into the vein. A final fluoroscopic image is obtained to confirm the appropriate final position and to ensure there is no kinking at the venotomy site. To allow for incorporation of the Dacron cuff within the subcutaneous tract, the cuff is inserted at least 1 cm away from the skin entry site.
Subcutaneous ports
As with TCVCs, ports are usually placed under moderate sedation. The use of prophylactic antibiotics remains controversial, because several small, randomized controlled trials failed to demonstrate the use of prophylactic antibiotics in reducing catheter-associated infections. 18 Therefore, the use of prophylactic antibiotics is largely based on institutional policy. If antibiotics are desired, then Ancef, vancomycin, or clindamycin may be considered. 19 Central access is obtained using the same abovementioned techniques under sonographic and fluoroscopy visualization. The port pocket is then created using sharp and blunt dissection. It is important to ensure that the subcutaneous tissue overlying the port is adequate and healthy to prevent skin necrosis or port exposure. The subcutaneous tunnel is then created using a metal tunneling device, extending from the apex of the chest incision to the neck incision and pulling the catheter out from the neck incision. A peel-away sheath is then placed over the guidewire, and the catheter is cut to the measured intravascular length and inserted through the sheath. In the antegrade fashion, the catheter is first placed via the peel-away sheath into the superior vena cava. With the tunneling device connected to the external end, this is tunneled from the neck incision site to the port pocket. The reservoir is then connected and inserted into the pocket. A final fluoroscopic image is obtained to ascertain appropriate positioning without kinking of the catheter. Generally, all ports are flushed with heparin at the conclusion of the procedure, as further discussed in the section below on catheter maintenance.
ANATOMIC ISSUES
The operator should be aware of anatomic abnormalities that predispose to difficult catheter placement and suboptimal catheter function. Anatomic abnormalities that predispose to CVC misplacement can be divided into internal and external factors. External factors cause central vein obstruction by physical venous compression. Benign causes of compression include thyroid goiter, thymoma, cystic hygroma of infectious etiologies (such as histoplasmosis), tuberculosis, or syphilis. Malignant causes of compression include lung cancer, breast cancer, lymphoma, or germ cell tumors. Most commonly, these malignancies cause narrowing or occlusion of the superior vena cava, which makes catheter placement difficult. Other issues that potentially alter standard superior vena cava positioning include mediastinal shift from pneumonectomy, pneumothorax, and pleural effusions. 20 Acquired internal abnormalities of the central veins are much more common than external compressive elements. Acquired abnormalities include central venous stenosis or thrombosis. Central venous stenosis and obstruction are strongly associated with previous CVC and pacemaker placement. [21] [22] [23] Additional risk factors include multiple prior CVC placements, longer catheter dwell times, poor catheter tip positioning, and venous location of previous catheters. CVCs placed by subclavian access have a reported central venous stenosis/occlusion rate of 42% versus 10% with catheters placed through the internal jugular vein. 22, [24] [25] [26] There is also an increased rate of central venous narrowing when a catheter is placed through a left-sided access, which may be related to the tortuous venous course from a left-sided approach. [26] [27] [28] There is a high reported incidence of large-bore hemodialysis catheters causing venous stenosis 29, 30 ; however, there is no literature available that assesses catheter diameter with the incidence of central venous narrowing. 31 Congenital abnormalities also predispose to challenging CVC placement. Persistent left-sided or double superior vena cava, dextrocardia, variations of the inferior vena cava caused by variations in embryogenesis, azygous vein abnormalities, and partial anomalous pulmonary venous drainage 20 are anatomic variations of which the operator must be aware when placing a CVC in this patient population. Cross-sectional imaging may be necessary to appropriately assess the anatomy before CVC placement.
Complications of device placement
Complications related to intravascular device placement can be categorized into three categories: 1) periprocedural/immediate complications, 2) early complications (within 30 days after placement), and 3) late complications (30 days after placement). 1 
Immediate complications
These complications occur during the procedure or immediately post-procedure. Incision site bleeding or hematoma is the most common, with reported incidence of 1% to 3%, and most are self-limiting. 32 A purse-string stitch may be necessary to allow for adequate hemostasis at the skin entry site after placement of tunneled largebore catheters. Several hemostatic collagen dressings that are commercially available, including QuickClot or Destat, may also be used in continual oozing at the neck incision site. Transient arrhythmias can be triggered during placement of the catheter, particularly with manipulation of the guidewire. This may manifest as self-limiting, premature ventricular contractions or supraventricular tachycardia, which may require reversal medications.
Inadvertent arterial puncture or pleural puncture is exceedingly rare with the widespread use of sonographic guidance during access, occurring less than 1% of cases. 1 When an arterial puncture occurs, the needle should be removed and 5 to 10 minutes of manual pressure is recommended before a repeat puncture. 32 Finally, a very rare, but dreaded, periprocedural complication is introduction of air embolus, with a reported incidence of 1%. 1 This occurs when there is an open communication of the central venous system to air. This can be controlled by meticulous flushing of all catheters and sheaths used for placement. Should an air embolism occur, the patient should immediately be placed in the left lateral decubitus position to keep further air bubbles from traveling to the main pulmonary artery. 33 Although most air embolisms are self-limiting, large embolisms have been associated with bradycardia, high morbidity, and mortality 33 ( Fig. 1) . 
Early complications
These complications occur within the first 30 days after placement of the catheter. Some of the most important early complications are catheter-related or skin site infections, which are the main factor limiting the longevity of the implanted device. Purulent discharge with erythema around the subcutaneous pocket or along the catheter track should prompt removal of the implanted device with a short course of antibiotics. Tunneled dialysis catheters with exposed Dacron cuffs should be promptly exchanged. Controversy remains whether patients with tunneled dialysis catheters who have asymptomatic bacteremia, with resolution after antibiotics, warrant a catheter exchange. 34 Catheter malfunction can happen any time after initial placement. This may be related to issues along the course of the catheter, including malposition of the catheter tip, intraluminal thrombosis, or formation of a fibrin sheath at the catheter tip. It is also prudent to ensure there is no kinking or fracture of the catheter (Fig. 2) . This can be confirmed with a plain radiograph. Although this is a rare occurrence, pinch-off syndrome has been described in subclavian venous catheters and is thought to be secondary to compression of the catheter between the first rib and the clavicle (Fig. 3) .
Other potential complications include catheter tip retraction into the superior vena cava or azygous vein. Over time, because of anatomic factors (such as heavier breast tissue or soft tissue in the neck), the catheter tip can retract, which necessitates revision. 1 
Late complications
Late complications usually occur 30 days beyond the initial placement. The most important complications in this category include venous stenosis and central venous occlusion.
1 Catheter-related infection, mainly catheterrelated bacteremia, also can be seen 30 days beyond the initial placement due to frequent access of the catheter, especially in the setting of hemodialysis. The overall rate of catheter-related bacteremia with TCVCs is reportedly 1.6/1000 catheter days. 12 An in-depth analysis of catheterrelated infection is beyond the scope of this article.
MANAGING CATHETER-RELATED ISSUES: FIBRIN SHEATHS
Despite the technical ease of placement of CVCs, it is critical to become familiar with nuances that ensure proper catheter function. The most common causes of catheter malfunction are fibrin sheath formation and intraluminal thrombus. 35 Clinically, a fibrin sheath manifests as an ability to flush the catheter but not aspirate, which is caused by a simulated one-way valve mechanism. Intraluminal thrombus manifests as an inability to flush or aspirate (Fig. 4) . The reported incidence of fibrin sheath formation varies in the literature but occurs in as many as 47% to 100% of patients. 36, 37 Fibrin sheaths are a heterogeneous matrix of debris and cells that form around the intravascular portion of catheters. [38] [39] [40] The sheath is composed of a heterogeneous matrix of platelet-fibrin thrombi, smooth muscle cell layers, and collagen layers. In addition to catheter malfunction, fibrin sheaths increase the risk of thrombus formation, infection, and pulmonary embolism after removal. 41, 42 Fibrin sheaths may form at any time after catheter placement. In fact, it has been demonstrated that fibrin sheath formation occur as early as 24 hours. 41 Catheter dysfunction occurs when the sheath covers the end hole(s) of the catheter. Venography can confirm the diagnosis of a fibrin sheath. Venography is performed with diluted contrast medium through each port using digital subtracted imaging over the chest. 42 If a fibrin sheath is suspected, then alteplase (a tissue plasminogen activator [tPA]) is infused with enough volume to fill each lumen and allowed to dwell. In the literature, there is not a consensus on tPA dosing and dwell time, which reflects the various degrees of overall success with this approach. Dose recommendations for tPA range from 1 to 2.5 mg, and dwell methods range from hours to days. 43 At our institution, tPA at 1 mg/mL is instilled with enough volume to fill each lumen with a dwell time of 2 hours. Short-term success rates after tPA infusion (defined as less than 30 days) ranges from 59% to 97%. Long-term (defined as greater than 30 days) patency rates range from 34% to 60%. The function of tPA infusion is to extend patency in the short term to plan for future catheter-related interventions or new placement. 44 If tPA therapy fails, then other interventions may be pursued, such as transcatheter thrombolytic infusion, angioplasty/stripping of the fibrin sheath, catheter exchange, or new catheter placement. These catheterrelated procedures are performed by Interventional Radiologists. 44 The continuing development of catheter biomaterials, coatings, and tip design reflects the clinical problem posed by the formation of fibrin sheaths.
CATHETER FLUSHING AND LOCKING
It is accepted practice that all catheters should be flushed and locked to ensure catheter patency and prevent thrombosis. 45 Solutions used most often are 0.9% sodium chloride solution, sodium citrate, and solutions containing heparin. The goal of catheter flushing is to remove debris and fibrin deposits in the catheter and/or port reservoir. The goal of an adequate catheter lock is prevention of premature termination of catheter function by maintaining patency when the catheter is not in use. However, there is a paucity of societal guidelines for practitioners on medication, dosing, and frequency of flushing. This is directly due to the lack of methodologically sound randomized controlled studies.
A review and analysis of all available published guidelines to maintain patency of central venous access are diverse and wide-ranging. 46 The recommendations of these societies are conflicting, are not based on randomized trails, and largely are constructed on catheter manufacturer's recommendations. [47] [48] [49] [50] [51] For example, flushing frequency recommendations for CVCs vary from no recommendation, regular intervals, after each use, and weekly when not in use. The Infusion Nurses Society recommends flushing all catheters routinely at established intervals and with preservative-free saline solutions or other solutions, as recommended by the manufacturer. 49 The Infusion Nurses Society also recommends using heparincontaining solutions at the lowest possible concentration in combination with physiologic saline to flush CVCs. 49 The British Committee for Standards in Hematology recommends flushing either after each use or weekly to maintain catheter patency. They also state that flushing with heparin versus saline is controversial and recommend flushing using 10 mL saline with or without heparin. 48 The National Collaborating Centre for Nursing and Supportive Care states a preference for saline flushes; however, they advise the use of heparin when recommended by the catheter manufacturer. 50 None of these societal guidelines offer flushing/locking medications or frequency recommendations. Optimal flushing solutions, solution volumes, and concentrations of medication used to prevent occlusion in patients with CVCs are not provided by any major society. Multiple systematic reviews have not found an increase in efficacy of using heparin to prevent thrombus formation versus normal saline. 48 It is reported that rates of catheter thrombus formation are equivalent whether saline or heparin is used. 45 58 Typical flushing recommendations for a CVC are a 10-mL flush (saline, heparin, or heparin and saline) for all catheters after the administration of fluids, drugs, or blood sampling. Frequency of flushing can be either every 8 to 12 hours in the setting of continuous use. If viscous products (such as total parenteral nutrition, blood components, or contrast media) are used, then a 20-mL flush may be considered. When catheter locking, recommendations are to use 1.5 mL for non-tunneled CVCs. For largebore TCVCs and IVADs, the amount used is usually determined to approximate the volume of the catheters (usually from 1.6 to 3 mL, depending on the length and French size of the catheter). If a high concentration of heparin is used for catheter locking, then the volume used should closely approximate the volume of the catheter lumen to avoid administering excess heparin into the circulation. Potential locking regimens include every 8 to 24 hours for short-term catheters, weekly for long-term catheters, and every 6 to 8 weeks for IVADs. 45 Dose ranges that may be used are as follows: normal saline, 0.9%; heparin, 10 to 10,000 unit/mL; and sodium citrate, 4%. 59 The concentration of sodium citrate should not exceed 4% because of the risk of inducing metabolic abnormalities. [59] [60] [61] [62] Choices of flushing/locking solutions and concentrations are entirely institution-dependent. Regardless of the type of locking solution used, it is best to aspirate and withdraw the lock when accessing the catheters before flushing. Given the lack of consensus on flushing and locking protocols, our institutional policy is described below. For non-tunneled CVCs, TCVCs, and IVADs that are not used for hemodialysis or apheresis, we recommend locking each lumen after every use with heparin at 10 units/mL. Large-bore catheters typically require higher concentrations and volumes of heparin. 45 Thus, for hemodialysis or apheresis catheters, we recommend locking with heparin at 1000 units/mL. If a patient has a heparin allergy, then normal saline may be used in its place. 63 The volume and concentration of heparin should be taken into consideration due to potential associated risks, including coagulation disorders, hypersensitivity reactions, and heparininduced thrombocytopenia. 63 The locking volume must be sufficient to fill each lumen of the catheter. Because there is leaking of the lock over time into the vasculature, catheters should be overfilled by 15% to 20%. The intraluminal volume can be found by referring to the catheter manual. In the case of a trimmed catheter, the volume may be calculated using a mathematic formula. 64 Further studies are needed along with societal recommendations to guide clinicians on medication agents, concentrations, and regimens to optimize catheter patency.
CONCLUSION
CVCs play an integral role in the management of patients with acute and chronic disease processes. The choice of a CVC is important, depending on the duration and flow rates required for therapy. Although CVCs are crucial to treatment, careful attention is required because they are prone to infection and dysfunction. Cases of catheter dysfunction may be treated by medication administration, although they often require revision by Interventional Radiology. Proper catheter maintenance is required to minimize complications and achieve the longest possible catheter life.
